Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis
Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Cyfraniad i Gynhadledd
Fersiynau electronig
Dangosydd eitem ddigidol (DOI)
There are concerns with the National Institute for Health and Care Excellence (NICE) conditional approval process with respect to the quality and reliability of the methods of evidence generation, analysis, and reporting; and on the increasing focus on OwR (only with research) in preference to OiR (only in research). Our study critically appraises the methods, quality, and risk of bias of the evidence generated in response to NICE conditionally approved technologies.
| Iaith wreiddiol | Saesneg |
|---|---|
| Teitl | OP41 Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis. |
| Is-deitl | Abstracts from the HTAi 2024 Meeting in Seville, Spain |
| Cyhoeddwr | International Journal of Technology Assessment in Health Care. |
| Cyfrol | 40 |
| Argraffiad | Special Issue S1 |
| Dynodwyr Gwrthrych Digidol (DOIs) | |
| Statws | Cyhoeddwyd - 7 Ion 2025 |
| Digwyddiad | Health Technology Assessment International (HTAi) 2024 Meeting: Oral presentation - Seville, Sbaen Hyd: 15 Meh 2024 → 19 Meh 2024 https://htai.org/event/htai-2024-annual-meeting/ |
Cynhadledd
| Cynhadledd | Health Technology Assessment International (HTAi) 2024 Meeting |
|---|---|
| Gwlad/Tiriogaeth | Sbaen |
| Dinas | Seville |
| Cyfnod | 15/06/24 → 19/06/24 |
| Cyfeiriad rhyngrwyd |